About this Journal Submit a Manuscript Table of Contents 
ISRN Oncology
Volume 2012 (2012), Article ID 768190, 10 pages
doi:10.5402/2012/768190
Clinical Study

Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

Michiko Takakura,1 Akira Yokomizo,2 Yoshinori Tanaka,3 Michimoto Kobayashi,3 Giman Jung,3 Miho Banno,4 Tomohiro Sakuma,4 Kenjiro Imada,2,5 Yoshinao Oda,5 Masahiro Kamita,1 Kazufumi Honda,1 Tesshi Yamada,1 Seiji Naito,2 and Masaya Ono1

1Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
3New Frontiers Research Laboratories, Toray Industries, Inc., 10-1 Tebiro, Kanagawa, Kamakura 248-8555, Japan
4Bio Science Department, Research and Development Center, Mitsui Knowledge Industry Co., Ltd., 2-7-14 Higashinakano, Nakano-Ku, Tokyo 164-8555, Japan
5Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Received 17 September 2012; Accepted 2 October 2012

Academic Editors: A. E. Bilsland, B. Comin-Anduix, G. Ferrandina, and S. Holdenrieder

Copyright © 2012 Michiko Takakura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Flow chart of 2DICAL analysis: In the first step, 2DICAL discovers candidate peaks via the differential analysis of LC-MS peaks. The candidate peaks are identified by targeted tandem MS in the second step.

  1. Supplementary Figure